Video

Dr Ilene Hollin: One-Size-Fits-All to Value Doesn't Work

A one-size-fits-all approach to value is impossible in the US healthcare system, but a pluralistic approach is extremely complex to implement, says Ilene Hollin, PhD, MPH, the National Pharmaceutical Council and University of Southern California Schaeffer Center’s Postdoctoral Health Policy Fellow.

A one-size-fits-all approach to value is impossible in the US healthcare system, but a pluralistic approach is extremely complex to implement, says Ilene Hollin, PhD, MPH, the National Pharmaceutical Council and University of Southern California Schaeffer Center’s Postdoctoral Health Policy Fellow.

Transcript (slightly modified)

Is a one-size-fits-all approach to value possible in US healthcare?

It’s not possible to have a one-size-fits-all approach to value assessment in the US healthcare system. We need a tailored approach, and to do so this means that we need to understand, define, and measure value accurately, and then tailor our approach to the stakeholder, to the health condition, and to the sub-population. This is imperative because there are substantial repercussions for reimbursement, patient access, and patient outcomes. It’s also important that we have a tailored approach because this is what will help drive innovation and make sure that future therapies are developed with what the patients want in mind.

What are the challenges of dealing with a pluralistic approach to value assessment?

The challenges of pluralistic approach to value assessment are that we have to account for individual preferences while making decisions at a population level. This is extremely complex to implement in a real-world application. It means highly sophisticated formulary designs and highly sophisticated reimbursement arrangements.

Related Videos
Kimberly Westrich, MA, chief strategy officer at the National Pharmaceutical Council
Sam Peasah, PhD, MBA, RPh, director for the Center of High-Value Health Care at the University of Pittsburgh Medical Center
Jawad Haider Butt, MD, PhD
Laura Bobolts, PharmD, BCOP, senior vice president of clinical strategy and growth at OncoHealth
Barry Byrne, MD, PhD, Powell Gene Therapy Center at the University of Florida
JC Scott, CEO and president, PCMA
Caspian Oliai, MD, MS, a medical oncologist and hematologist and medical director of the UCLA Bone Marrow Transplantation Stem Cell Processing Center
Neha Kashalikar, PharmD, director of strategic pharmacy consulting, MassHealth
Adam Colburn, JD, vice president for congressional affairs, AMCP
Katrina Ortblad, ScD, MPH, Fred Hutch Cancer Center
Related Content
AJMC Managed Markets Network Logo
CH LogoCenter for Biosimilars Logo